J. Goldman & CO LP Esperion Therapeutics, Inc. Call Options Transaction History

J. Goldman & CO LP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	BUY	$5.09 - $8.5 $2.41 Million - $4.02 Million	472,500 New	472,500 $2.94 Million
Q2 2020 Aug 14, 2020	BUY	$30.04 - $51.31 $1.35 Million - $2.31 Million	45,000 New	45,000 $2.31 Million
Q1 2020 May 15, 2020	SELL	$27.44 - $73.84 $74,088 - $199,368	-2,700 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$35.4 - $59.82 $2.21 Million - $3.73 Million	-62,300 Reduced 95.85%	2,700 $161,000
Q1 2018 May 15, 2018	SELL	$65.94 - $80.76 $12 Million - $14.7 Million	-182,000 Reduced 73.68%	65,000 $4.7 Million
Q4 2017 Feb 14, 2018	BUY	$43.47 - $67.43 $8.48 Million - $13.1 Million	195,000 Added 375.0%	247,000 $16.3 Million
Q3 2017 Nov 14, 2017	BUY	$43.8 - $52.77 $2.28 Million - $2.74 Million	52,000	52,000 $2.61 Million

207

128M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $168M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.